Molecularly Targeted Therapies in Multiple Myeloma
Open Access
- 16 April 2014
- journal article
- review article
- Published by Hindawi Limited in Leukemia Research and Treatment
- Vol. 2014, 1-8
- https://doi.org/10.1155/2014/976567
Abstract
Multiple myeloma (MM) is a hematological malignancy that remains incurable because most patients will eventually relapse or become refractory to the treatments. Although the treatments have improved, the major problem in MM is the resistance to therapy. Novel agents are currently in development for the treatment of relapsed/refractory MM, including immunomodulatory drugs, proteasome inhibitors, monoclonal antibodies, cell signaling targeted therapies, and strategies targeting the tumor microenvironment. We have previously reviewed in detail the contemporary immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies therapies for MM. Therefore, in this review, we focused on the role of molecular targeted therapies in the treatment of relapsed/refractory multiple myeloma, including cell signaling targeted therapies (HDAC, PI3K/AKT/mTOR, p38 MAPK, Hsp90, Wnt, Notch, Hedgehog, and cell cycle) and strategies targeting the tumor microenvironment (hypoxia, angiogenesis, integrins, CD44, CXCR4, and selectins). Although these novel agents have improved the therapeutic outcomes for MM patients, further development of new therapeutic agents is warranted.Keywords
This publication has 73 references indexed in Scilit:
- AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse modelBlood Cancer Journal, 2011
- Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trialBritish Journal of Haematology, 2011
- Bevacizumab: current updates in treatmentCurrent Opinion in Oncology, 2010
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapyBlood, 2009
- Preferential Induction of EphB4 over EphB2 and Its Implication in Colorectal Cancer ProgressionCancer Research, 2009
- The role of microenvironment in tumor angiogenesisGenes & Nutrition, 2008
- Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myelomaBlood, 2006
- mTOR and cancer: insights into a complex relationshipNature Reviews Cancer, 2006
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaThe New England Journal of Medicine, 2005